Articles.
Clear, evidence-based writing on midlife health: perimenopause and menopause, hormone therapy, weight and metabolic change, testosterone, hair, and skin. Focused on what research actually says about the questions women ask.
Browse by what you want to learn about
Across midlife health
Evidence-based writing across midlife health, including hormones, weight, hair, skin and more. Each topic opens with the best place to start; pick one on the left to browse everything in it.
Perimenopause
The years before your last period: what is changing, how long it lasts, and what the evidence says actually helps.
Start hereHow Long Does Perimenopause Last? Usually Years, Not WeeksPerimenopause usually lasts years, not weeks. The Office on Women's Health describes the transition as lasting 2 to 8 years before periods stop, with about 4 years being typical, while a Study of Women's Health Across the Nation menstrual-calendar analysis found adjusted median menopausal-transition duration ranging from 4.37 to 8.57 years depending on age at onset. Menopause itself is confirmed after 12 months without a period when another cause is not explaining the pattern. [1] [2]More in PerimenopauseView all →
- What Is Perimenopause? Symptoms, Timing, and DiagnosisPerimenopause is the menopause transition: periods may become less predictable, and symptoms such as hot flashes, night sweats, sleep disruption, mood change, vaginal dryness, acne, or heavier bleeding can appear before the final period. The Stages of Reproductive Aging Workshop +10 (STRAW+10) framework stages the transition around menstrual-cycle changes and the final menstrual period, while American College of Obstetricians and Gynecologists guidance says hormone testing is usually unnecessary when age, symptoms, and period changes fit perimenopause. [1] [2] Menopause is confirmed only after 12 months without a period, unless hormonal contraception, surgery, pregnancy, or another medical cause obscures the pattern.
- Perimenopause vs Menopause: How to Tell the DifferencePerimenopause is the transition when cycle timing changes and symptoms such as hot flashes or night sweats may start. Menopause is confirmed after 12 months without a period when pregnancy, hormonal contraception, surgery, or another medical cause does not explain the bleeding pattern. The Stages of Reproductive Aging Workshop +10 (STRAW+10) framework stages the transition around menstrual-cycle changes and the final menstrual period, and American College of Obstetricians and Gynecologists guidance says hormone testing usually is not needed when age, symptoms, and period changes fit perimenopause. [1] [2]
- Why Perimenopause Symptoms Can Come and GoPerimenopause symptoms can come and go because the transition is staged by changing cycle patterns, not by one steady daily hormone level. American College of Obstetricians and Gynecologists guidance says hormone testing usually is not needed when age, symptoms, and period changes fit perimenopause, and the Office on Women's Health says as many as 3 in 4 women have hot flashes. [1] [2] [5] Fluctuation can be expected, but heavy bleeding, bleeding between periods, bleeding after sex, postmenopausal bleeding, symptoms before age 40, or neurologic/chest symptoms should be evaluated instead of being filed under normal hormones.
Menopause & HRT
Hormone therapy, hot flashes, sleep and mood. Plain-language summaries of what randomized evidence shows about hormonal and non-hormonal menopause care.
Start hereWhat Is Menopause? The 12-Month RuleMenopause is the point reached after 12 months in a row without a period or spotting, when pregnancy, hormonal contraception, surgery, medication, or another medical cause is not explaining the bleeding pattern. It is confirmed in hindsight, not on the day symptoms start. Perimenopause is the transition before that point, and postmenopause is the life stage after it. American College of Obstetricians and Gynecologists guidance says hormone testing usually is not needed when age, symptoms, and period changes fit the transition; bleeding after menopause should be evaluated. [1] [2] [3] [4]More in Menopause & HRTView all →
- Menopause Symptoms After 45: Common Patterns and Red FlagsMenopause symptoms are not one symptom and not one timeline. Common patterns include hot flashes, night sweats, sleep disruption, mood changes, brain fog, vaginal dryness, painful sex, urinary urgency or recurrent UTIs, joint aches, skin and hair changes, and weight or waist changes. Cycle changes usually belong to perimenopause, while bleeding after 12 months without a period is postmenopausal bleeding and should be evaluated. The Stages of Reproductive Aging Workshop +10 (STRAW+10) framework defines the final menstrual period retrospectively after 12 months without bleeding, and American College of Obstetricians and Gynecologists guidance says hormone testing usually is not needed when age, symptoms, and period changes fit the transition. [1] [2]
- Hormone Therapy After Menopause: Benefits, Risks, and TimingHormone therapy can help bothersome hot flashes, night sweats, genitourinary syndrome of menopause, and selected bone-loss prevention decisions, especially for healthy women younger than 60 or within 10 years of menopause. Women's Health Initiative still defines the safety frame: estrogen plus progestin increased coronary, breast-cancer, stroke, and pulmonary-embolism risks, while estrogen alone in women with hysterectomy raised stroke risk and lowered hip-fracture risk. [2] [3] Route, uterus status, timing, contraindications, and personal risk decide fit. FDA-approved estradiol or micronized progesterone also differs from custom-compounded bioidentical therapy, which American College of Obstetricians and Gynecologists says should not be routine when approved options exist. [8]
- Bioidentical HRT: FDA-Approved vs CompoundedBioidentical hormone replacement therapy can mean FDA-approved estradiol or micronized progesterone products, or custom-compounded hormones marketed as natural or individualized. A 2023 American College of Obstetricians and Gynecologists Clinical Consensus says safety and effectiveness marketing claims for compounded bioidentical menopausal hormone therapy lack support and that these products should not be prescribed routinely when FDA-approved options exist. [1] A 2022 review found inadequate evidence for breast cancer, endometrial cancer, or cardiovascular outcomes. [3] The safer question is whether a clinician can document a patient-specific reason for compounding. [7]
Weight loss & metabolic health
GLP-1 medications, insulin resistance, PCOS and metabolic health after 40 - what the evidence says about treatment fit, trade-offs, and realistic expectations.
Start hereWaist Circumference After Menopause: What It Tells YouWaist circumference is useful after menopause because body mass index can miss a shift toward visceral abdominal fat. In the Study of Women's Health Across the Nation Heart study, visceral adipose tissue rose 8.2% per year in the 2 years before the final menstrual period and 5.8% per year after it. A 2020 consensus statement argues that waist circumference adds risk information beyond body mass index. In practice, waist measurement belongs next to blood pressure, three-month blood sugar marker or glucose testing when appropriate, lipids, medication review, sleep, strength, and symptom history. [1]More in Weight loss & metabolic healthView all →
- Tirzepatide vs Semaglutide After MenopauseTirzepatide vs semaglutide after menopause should be framed around direct obesity-trial evidence and individual eligibility, not a blanket winner. Tirzepatide produced more average weight loss than injectable semaglutide in a 72-week head-to-head obesity trial, but the study was not designed around menopause. For a midlife woman, the right comparison is not just which drug lowers weight more. It is whether her body mass index, metabolic risk, contraindications, side-effect tolerance, cost, and maintenance plan make either prescription route appropriate. [1]
- Menopause Weight Loss: What Actually Changes After 45Menopause weight loss is harder to manage well when the only metric is scale weight. Study of Women's Health Across the Nation body-composition data suggest that around the menopause transition, fat gain accelerates and lean mass declines, even when total weight does not show the whole change. [1] The practical plan after 45 should check waist, three-month blood sugar marker, blood pressure, lipids, sleep apnea, medications, thyroid status when indicated, protein intake, resistance training, bone risk, constipation, glucagon-like peptide-1 eligibility, and maintenance. The goal is not simply "lose weight." It is to reduce cardiometabolic risk while protecting muscle, bone, function, and long-term follow-up.
- GLP-1 Eligibility After MenopauseGlucagon-like peptide-1 eligibility after menopause starts with labeled body mass index and weight-related condition criteria, but it does not end there. Current Wegovy labeling includes chronic weight management for adults with obesity or overweight plus a weight-related comorbidity, cardiovascular event-risk reduction in adults with established cardiovascular disease and obesity or overweight, and noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. [1] Current Zepbound labeling includes chronic weight management and moderate to severe obstructive sleep apnea in adults with obesity. [2] A good screen also reviews contraindications, severe gastrointestinal disease, gallbladder and pancreatitis history, kidney/dehydration risk, medications, pregnancy plans, lean mass, bone risk, and follow-up capacity.
Hair thinning & loss
Widening parts, shedding and midlife hair thinning - how clinicians sort causes, lab clues, and oral or topical treatment options by pattern and history.
Start hereWidening Part After Menopause: Pattern or Shedding?A widening part after menopause often points toward female-pattern hair loss, but the first decision is pattern, not product. Gradual central thinning with a preserved frontal hairline fits female-pattern hair loss more than sudden diffuse shedding. Heavy shedding that starts 2 to 4 months after illness, surgery, rapid weight loss, medication change, low intake, low ferritin, or thyroid disease points toward telogen effluvium or a mixed picture. Scalp pain, scale, pustules, shiny scarring, patchy loss, eyebrow loss, or a rapidly receding front hairline should move the plan toward dermatology review before routine hair-growth treatment. [6]More in Hair thinning & lossView all →
- How to Get Prescribed Spironolactone for Hair Loss After MenopauseTo get prescribed spironolactone for hair loss, the useful visit is not a product request. It is a diagnosis and safety review. Spironolactone may be discussed off label when hair loss looks androgen-sensitive, such as gradual crown or part-line thinning with acne, facial hair, polycystic ovary syndrome history, or other androgen clues. A clinician should first separate female pattern hair loss from sudden shedding, scarring disease, thyroid or iron issues, medication effects, and rapid weight-loss triggers. Then the prescription screen should cover blood pressure, kidney function, potassium, potassium-raising medicines or supplements, pregnancy potential when relevant, and how response will be measured over months. [1] [2] [5] [7]
- Oral Minoxidil for Women After MenopauseOral minoxidil can be discussed for women with midlife hair thinning, but it is an off-label prescription route for hair growth. The strongest randomized evidence in female pattern hair loss still belongs to topical minoxidil. Low-dose oral minoxidil has large observational safety data and smaller female-pattern-hair-loss cohorts, so the useful frame is it as a clinician-monitored option, not a first-step over-the-counter swap. [1]
- Menopause Hair Loss Treatment: Options and What to CheckMenopause can coincide with hair thinning, but treatment should start by identifying the pattern: female pattern hair loss, telogen effluvium, alopecia areata, scarring hair loss, iron or thyroid issues, medication effects, or scalp disease. Topical minoxidil has randomized evidence in women with female pattern hair loss. Hormone therapy is not a first-line hair-loss treatment by itself. [1]
Testosterone for women
Testosterone for women: what low testosterone looks like, what the still-emerging evidence shows, and how therapy is evaluated and monitored.
Start hereTestosterone for Fatigue After Menopause: Does It Help?Testosterone should not be presented as a general fatigue treatment for women after menopause. In a 2019 meta-analysis of 36 randomized trials with 8,480 participants, testosterone improved sexual-function outcomes in postmenopausal women, including a 0.85 mean difference in satisfying sexual event frequency, but no effects were reported for cognitive measures or body composition. [3] Global consensus, International Society for the Study of Women's Sexual Health, and Endocrine Society guidance keep the evidence-supported use narrow: carefully assessed hypoactive sexual desire disorder, with dosing and blood-level monitoring to avoid supraphysiologic exposure. Fatigue needs a broader review that can include sleep, thyroid disease, anemia, depression, medications, pain, hot flashes, alcohol, and metabolic health.More in Testosterone for womenView all →
- How Quickly Does Testosterone Therapy Work?For women after menopause using testosterone for carefully assessed hypoactive sexual desire disorder, the honest timeline is weeks to months, not days. International Society for the Study of Women's Sexual Health says average efficacy emerges about 6 to 8 weeks after starting therapy, many women feel improvement after 4 weeks, maximal effects in sexual desire and satisfactory sexual events occur around 12 weeks, and therapy should not continue beyond 6 months without clinically meaningful improvement. [1] This timeline does not support using testosterone as a fast treatment for fatigue, weight, mood, muscle, cognition, or anti-aging. [2] [5]
- Testosterone Therapy for Women After MenopauseThe strongest consensus-backed use of testosterone therapy for women is hypoactive sexual desire disorder after menopause, after a clinician checks relationship, mood, medication, pain, sleep, estrogen, and medical factors. In a 2019 meta-analysis of 36 randomized trials with 8,480 women, testosterone improved sexual-function outcomes, but blood testosterone alone does not diagnose the problem and evidence is not strong enough to use testosterone as a general treatment for fatigue, weight, mood, cognition, or anti-aging. [1]
- Low Testosterone Symptoms in Women After MenopauseFatigue, weight gain, low mood, hair change, and low desire can happen after menopause, but they do not diagnose low testosterone by themselves. The strongest evidence-backed use of systemic testosterone in women is treatment of hypoactive sexual desire disorder after a biopsychosocial assessment. Testosterone levels are used for baseline and monitoring, not as a standalone symptom-score diagnosis. [1]
Skin, acne & pigmentation
Prescription-strength skin care for midlife skin changes - tretinoin, acne, melasma, dark spots and pigmentation questions grounded in dermatology evidence.
Start hereDry Itchy Skin After Menopause: Moisturizer Plan and Red FlagsDry itchy skin after menopause is often xerosis, so a fragrance-free cream or ointment routine is a reasonable first step. It should be checked when itch is severe, widespread, sleep-disrupting, linked to a new medicine, localized to the vulva or one nerve area, paired with rash, jaundice, dark urine, infection, bleeding, or a changing spot, or not improving after consistent barrier care. [1]More in Skin, acne & pigmentationView all →
- Prescription Skin Care After MenopausePrescription skin care after menopause should start with the diagnosis, not with the strongest cream. Acne, rosacea, melasma, photoaging, actinic keratoses, and changing lesions can overlap in midlife but use different treatments. The 2024 American Academy of Dermatology acne guideline strongly recommends benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline for appropriate acne patients, while pigment care may involve hydroquinone, triple-combination therapy, azelaic acid, or procedures after diagnosis. [1] [4] A clinician-guided skin assessment should separate the problem first, then choose a prescription category with irritation, pigment, sun, pregnancy-potential, medication, and red-flag review.
- Tretinoin After Menopause: Results, Irritation, and Safe UseTopical tretinoin has randomized evidence for photodamaged facial skin and wrinkles, but it is not a menopause hormone treatment. A 2025 meta-analysis included 8 randomized trials with 1,361 patients and found improvement in fine wrinkles and coarse wrinkles; an older 251-person multicenter trial found 79% of patients using 0.05% tretinoin improved after 24 weeks versus 48% using vehicle. [1] [2] The decision depends on irritation, sun protection, pregnancy screening when relevant, and whether the treatment target is photoaging rather than a changing lesion or estrogen-related dryness.
- Melasma After Menopause Treatment OptionsMelasma treatment after menopause should start with diagnosis and daily photoprotection, then match the treatment to skin type, hormone timing, irritation risk, and clot risk. In the Cochrane review, 20 randomized studies with 2,125 participants found triple-combination cream more effective than hydroquinone alone for lightening melasma (relative risk 1.58, 95% confidence interval 1.26-1.97). [1] Azelaic acid trials show a modest MASI advantage over hydroquinone, while lasers and light devices can improve scores but raise adverse-event risk. [2] [5] The safest plan is not "brighten first." It is diagnose, protect from UV and visible light, choose a topical category, reserve procedures for selected cases, and screen off-label oral tranexamic acid carefully.
Peptides for women
Peptides for women in midlife - what people use them for, where evidence is limited, and how a clinician evaluates whether an option may be appropriate.
Start herePeptides for Women After Menopause: Evidence, Safety, FDA Red FlagsPeptides are short chains of amino acids, but "peptide therapy" is not one evidence category. Some peptide drugs are FDA-approved for narrow indications, such as tesamorelin for excess abdominal fat in adults with HIV-associated lipodystrophy or bremelanotide for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Many clinic-marketed peptides for menopause, weight, recovery, skin, or energy have much weaker human evidence and may involve compounded products with safety and quality-control concerns. [1]More in Peptides for womenView all →
- Sermorelin for Women After Menopause: Evidence and SafetySermorelin after menopause should be treated as a growth hormone-axis evidence question, not as an established menopause treatment. Geref, a sermorelin acetate product, had FDA-approved history for pediatric growth-hormone deficiency and diagnostic use, but it was discontinued in 2008 and is not the same as a current compounded anti-aging product. [2] [3] In the most relevant older-adult growth hormone-releasing hormone analog study, 19 adults aged 55 to 71 had growth hormone/insulin-like growth factor 1 activation and increased skin thickness after 16 weeks, but weight and sleep did not improve, and lean-mass, insulin-sensitivity, well-being, and libido signals favored men rather than women. [1]
- CJC-1295 and Ipamorelin After Menopause: Do They Work?CJC-1295 and ipamorelin should not be treated as established menopause therapies. CJC-1295 increased growth hormone 2- to 10-fold for at least 6 days and insulin-like growth factor 1 1.5- to 3-fold for 9 to 11 days in healthy adults, but that was biomarker evidence, not a trial of women after menopause. Ipamorelin human data also show growth-hormone stimulation, while a 117-patient postoperative-ileus trial did not show significant efficacy differences on key outcomes. FDA safety materials also flag CJC-1295 and ipamorelin-related compounding concerns. [1]
- BPC-157 After Menopause: Evidence, FDA Status, and SafetyBPC-157 is not a menopause treatment with established benefits for women after menopause. A 2025 musculoskeletal review found only three human pilot reports: intra-articular knee pain, interstitial cystitis, and a 2-person intravenous safety/pharmacokinetic study. [1] FDA also lists BPC-157 among compounded bulk substances with safety uncertainties, including immunogenicity, peptide-impurity, and active-ingredient characterization concerns. [6] The July 23, 2026 FDA advisory-committee review is about possible 503A compounding-list status, not FDA approval of BPC-157 as a finished drug; FDA briefing materials propose that BPC-157 free base and BPC-157 acetate not be included on that list. [7] [8]